New diabetes clinical trial: Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

Published on: June 14, 2019 at 07:00PM
Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: TQ-F3083 capsule 5 mg;   Drug: TQ-F3083 capsule 10 mg;   Drug: TQ-F3083 blank analog capsule;   Drug: Linagliptin blank analog tablet;   Drug: Linagliptin tablet
Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting